The present invention relates to an ophthalmic pharmaceutical composition for topical administration comprising a therapeutically effective quantity of an active ingredient and/or combination with another active ingredient more particular said active ingredient is selected from a prostaglandin or a pharmaceutically acceptable salt or derivative thereof, a fluoroquinolone such as Levofloxacin and salts or derivatives thereof, a carbonic anhydrase inhibitor, such as Dorzolamide or salts thereof, a beta-adrenergic receptor antagonist, such as Timolol or salts thereof, a mast cell stabilizer such as cromoglicic acid or salts thereof, an α2-adrenoceptor antagonist such as brimonidine or salts thereof and/or combination of said active ingredients for the treatment of a condition affecting the exterior ocular surface, and a process for the preparation thereof, which exhibits enhanced corneal epithelial permeability.
